Combination treatment with both agents together further suppressed tumor volume and resulted in greater inhibition of CD44+/CD24− CSCs per tumor volume compared to single treatment with docetaxel or nPKC-θi2 (Figure 5B). This evidence concerns the gene CD44 and neoplasm.